Name | N-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide |
---|---|
Synonyms |
Ethanesulfonamide, N-[4-[4-[2-(difluoromethyl)-4-methoxy-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)-
N-{4-[4-[2-(difluoromethyl)-4-methoxy-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl}-2-(dimethylamino)ethanesulfonamide N-(4-{4-[2-(Difluoromethyl)-4-methoxy-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl}phenyl)-2-(dimethylamino)ethanesulfonamide N-(4-(4-(2-(difluoromethyl)-4-methoxy-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-2-(dimethylamino)ethanesulfonamide |
Density | 1.5±0.1 g/cm3 |
---|---|
Boiling Point | 769.9±70.0 °C at 760 mmHg |
Molecular Formula | C26H30F2N8O4S |
Molecular Weight | 588.629 |
Flash Point | 419.4±35.7 °C |
Exact Mass | 588.207886 |
PSA | 135.98000 |
LogP | 2.44 |
Vapour Pressure | 0.0±2.6 mmHg at 25°C |
Index of Refraction | 1.664 |
~% 1246203-32-6 |
Literature: Pathway Therapeutics Limited Patent: US2010/249099 A1, 2010 ; Location in patent: Page/Page column 83 ; US 20100249099 A1 |
Precursor 2 | |
---|---|
DownStream 1 | |